Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immatics N.V.

6.33
+0.43007.29%
Post-market: 6.330.00000.00%16:10 EDT
Volume:462.05K
Turnover:2.88M
Market Cap:769.47M
PE:-8.31
High:6.39
Open:5.99
Low:5.95
Close:5.90
52wk High:13.09
52wk Low:3.30
Shares:121.56M
Float Shares:58.79M
Volume Ratio:0.45
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7614
EPS(LYR):0.1490
ROE:-17.54%
ROA:-9.11%
PB:1.42
PE(LYR):42.49

Loading ...

Immatics NV reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Earnings Flash (IMTX) Immatics Posts Q2 Revenue From Collaboration Agreements 4.7M Euros

MT Newswires Live
·
Aug 13

Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.58 Euros a Share, vs. FactSet Est of 0.28 Euros Loss

MT Newswires Live
·
Aug 13

Immatics Q2 2025 Cash And Cash Equivalents As Well As Other Financial Assets Of $560.5M; Cash Reach Into 2H 2027

Benzinga
·
Aug 13

Immatics Q2 EPS $(0.68) Misses $(0.38) Estimate, Sales $5.500M Miss $14.270M Estimate

Benzinga
·
Aug 13

Immatics Announces Second Quarter 2025 Financial Results and Business Update

GlobeNewswire
·
Aug 13

Immatics NV expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 09

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

Insider Monkey
·
Jul 09

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM

TIPRANKS
·
Jun 19

Immatics NV Convened Annual General Meeting of Shareholders

Reuters
·
Jun 19

Cantor Fitzgerald Keeps Their Buy Rating on Immatics (IMTX)

TIPRANKS
·
Jun 03

Immatics announces presentation of data from ongoing Phase 1b trial on IMA203

TIPRANKS
·
Jun 02

Immatics NV Presents Promising Results from IMA203 PRAME Cell Therapy Trial at 2025 ASCO Meeting, Highlighting Strong Anti-Tumor Activity in Metastatic Melanoma

Reuters
·
May 31

Immatics Initiated at Buy by Deutsche Bank

Dow Jones
·
May 29

Immatics initiated with a Buy at Deutsche Bank

TIPRANKS
·
May 28

Immatics NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Immatics Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $19.54M Beat $15.42M Estimate

Benzinga
·
May 13

Immatics Q1 Sales $20.10M Beat $13.96M Estimate

Benzinga
·
May 13

Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update

Dow Jones
·
May 13

Immatics NV expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 10